Stem Cell Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 118 Pages | 納期: 2-3営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.07円
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 118 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次




第1章 イントロダクション

  • 調査の成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • 臍帯幹細胞についての意識の高まり
    • 幹細胞研究における臨床試験の承認の増加
    • 再生治療の選択肢に対する需要の高まり
    • 慢性疾患に対する治療選択肢を開発するための研究開発イニシアチブの高まり
  • 市場阻害要因
    • 高額な治療
    • 規制上の問題
    • 倫理的および道徳的枠組み
  • 業界の魅力 - ポーターのファイブフォース分析
    • 新規参入者の脅威
    • 買い手/消費者の交渉力
    • 売り手の交渉力
    • 代替製品の脅威
    • 業界内の競合の激しさ

第5章 市場セグメンテーション

  • 製品タイプ別
    • 成人幹細胞
    • ヒト胚細胞
    • 多能性幹細胞
    • 他の製品タイプ
  • 治療用途別
    • 神経学的障害
    • 整形外科治療
    • 腫瘍疾患
    • 糖尿病
    • 怪我と傷
    • 心血管障害
    • その他の治療用途
  • 治療タイプ別
    • 同種幹細胞療法
    • オートロジック幹細胞療法
    • 同系幹細胞療法
  • バンキングサービスおよび技術別
    • 幹細胞の取得と検査
    • 細胞生成
    • 拡張
    • 二次培養
    • 凍結保存
  • バンキングタイプ別
    • 公的
    • 民間
  • 地理
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Osiris Therapeutics Inc.
    • Pluristem Therapeutics Inc.
    • Thermo Fisher Scientific
    • Qiagen NV
    • Sigma Aldrich Corporation
    • Becton, Dickinson and Company
    • Stem Cell Technologies Inc.
    • AllCells LLC
    • Miltenyi Biotec
    • International Stem Cell Corporation

第7章 市場機会および将来動向

Product Code: 47511

The stem cell market was valued at USD 14.7 billion in 2020, and it is expected to reach approximately USD 26.40 billion in 2026, registering a CAGR of nearly 10.24% during the forecast period, 2021-2026. The growth of the market is attributed to the rising number of clinical trials and the growing adoption of stem cell therapies globally. In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19. According to a 2020 research article published in the scientific journal Aging and Disease (2020), mesenchymal stem cells are a safe and effective approach to the treatment of COVID-19. At least 10 projects have been registered in the official international registry for clinical trials, implicating the use of mesenchymal stem cells to patients with coronavirus pneumonia. However, it is still at an initial stage of study in relation to the market studied.

Stem cells are majorly used in regenerative medicine, especially in the field of dermatology. However, oncology is expected to grow at the highest rate due to a large number of pipeline products present for the treatment of tumors or cancers. With the increase in the number of regenerative medicine centers, the stem cell market is also expected to increase in the future.

One of the richest sources of stem cells is the umbilical cord, which possesses unique qualities and has greater advantages over embryonic stem cells or adult stem cells. There are an increasing number of stem cell banks, which collaborate with hospitals and increase awareness about the storage of cord blood units in families, particularly in the emerging markets. The support is increasing with the rising number of medical communities and government initiatives active in promoting the use of stem cells for the treatment of more than 100 diseases. Currently, there is an increase in the number of clinical trials for testing future treatment possibilities of cord blood. Over 200 National Institutes of Health (NIH)-funded clinical trials with cord blood are currently being conducted in the United States alone.

Key Market Trends

The Oncology Disorders Segment is Expected to Exhibit the Fastest Growth Rate Over the Forecast Period

The global cancer burden has been increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world. According to the World Health Organization (WHO), cancer is the second-leading cause of death across the world, with an estimated number of 9.6 million deaths in 2018, accounting for nearly one in six deaths.

Bone marrow transplant or stem cell transplant is a treatment for some types of cancer, like leukemia, multiple myeloma, neuroblastoma, or some types of lymphoma. For cancer treatments, both autologous and allogeneic stem cell transplants are done. Autologous transplants are preferred in the case of leukemias, lymphomas, multiple myeloma, testicular cancer, and neuroblastoma.

The major disadvantage associated with autologous stem cell transplants in cancer therapy is that cancer cells sometimes also get collected, along with stem cells, which may further put it back into the body during the therapy.

In case of allogeneic stem cell transplants, the donor can often be asked to donate more stem cells or even white blood cells, as per the requirement, and stem cells from healthy donors are free of cancer cells. However, the transplanted donor stem cells could die or be destroyed by the patient's body before settling in the bone marrow.

Moreover, due to the growing focus of stem cell-based research and the rising demand for novel treatments, several companies, such as Stemline Therapeutics, have been focusing on developing technologies and treatments to attack cancer cells, which may help the market grow. However, owing to the COVID-19 pandemic, the detection and treatment of new cancer cases are impended, which may slightly impact the segment growth in the year.

North America Captured The Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall stem cell market, with the United States contributing to the largest share in the market. The United States and Canada have developed and well-structured healthcare systems. These systems also encourage research and development. The increasing number of cancer cases is providing opportunities for market players. The major market players are focusing on R&D activities to introduce new stem cell therapies in the market.

For instance, the National Cancer Institute (NCI) had stated that the national expenditure on cancer care was expected to reach USD 156 billion by 2020. This factor is expected to boost the growth of the market in the future. In December 2019, the researchers at the National Eye Institute (NEI) launched a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD), a leading cause of vision loss among people aged 65 years and above.

In addition, the current situation of COVID-19 is another factor driving the growth of the market in the country, as research activities are undergoing for the treatment of COVID-19. Stem cell therapy can also be a promising approach for the treatment of COVID-19 in the future. For instance, on May 6, 2020, Lineage Cell Therapeutics received a grant of USD 5 million from the California Institute for Regenerative Medicine (CIRM) to support the use of VAC, Lineage's allogeneic dendritic cell therapy for the development of a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.

Competitive Landscape

The stem cell market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Thermo Fisher Scientific (Qiagen NV), Sigma Aldrich (a subsidiary of Merck KGaA), Becton, Dickinson and Company, and Stem Cell Technologies, is in turn, increasing the overall competitive rivalry in the market. The product advancements and improvement in stem cell technology by the major players are also increasing the competitive rivalry.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Awareness about Umbilical Stem Cell
    • 4.2.2 Rising R&D Initiatives to Develop Stem Cell Therapies and Increasing Approvals for Clinical Trials in Stem Cell Research
    • 4.2.3 Growing Demand for Regenerative Treatment Options
  • 4.3 Market Restraints
    • 4.3.1 Expensive Procedures
    • 4.3.2 Regulatory Complications
    • 4.3.3 Ethical and Moral Framework
  • 4.4 Industry Attractiveness- Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product Type
    • 5.1.1 Adult Stem Cell
    • 5.1.2 Human Embryonic Cell
    • 5.1.3 Pluripotent Stem Cell
    • 5.1.4 Other Product Types
  • 5.2 By Application
    • 5.2.1 Neurological Disorders
    • 5.2.2 Orthopedic Treatments
    • 5.2.3 Oncology Disorders
    • 5.2.4 Injuries and Wounds
    • 5.2.5 Cardiovascular Disorders
    • 5.2.6 Other Applications
  • 5.3 By Treatment Type
    • 5.3.1 Allogeneic Stem Cell Therapy
    • 5.3.2 Autologic Stem Cell Therapy
    • 5.3.3 Syngeneic Stem Cell Therapy
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Smith & Nephew PLC
    • 6.1.2 Pluristem Therapeutics Inc.
    • 6.1.3 Thermo Fisher Scientific
    • 6.1.4 Qiagen NV
    • 6.1.5 Merck KGaA (Sigma Aldrich)
    • 6.1.6 Becton, Dickinson and Company
    • 6.1.7 Stem Cell Technologies Inc.
    • 6.1.8 AllCells LLC
    • 6.1.9 Miltenyi Biotec
    • 6.1.10 International Stem Cell Corporation